›Empiric antibiotic therapy pending cultures
›Vancomycin 15-20 mg/kg IV every 8-12 hours, dosed to trough or AUC-based target, for gram-positive and MRSA coverage
›Cefepime 2 g IV every 8 hours for gram-negative and Pseudomonas coverage
›Narrow to culture-directed therapy once results available
›Superficial infection
›Local wound care and driveline immobilization
›Oral antibiotics may be adequate if no systemic signs, per VAD team direction
›Deep or pump-pocket infection
›IV antibiotics for a prolonged course (often weeks), guided by the VAD or infectious disease team
›Chronic suppressive antibiotic therapy is sometimes required for the life of the device if source control cannot be fully achieved
›Surgical debridement or device exchange in refractory or pocket-involved infection
Gastrointestinal bleeding and the anticoagulation dilemma
›Mechanism
›Acquired von Willebrand syndrome from shear-induced loss of high-molecular-weight multimers plus arteriovenous malformations from chronic non-pulsatile flow and mucosal hypoxia
›Bleeding risk is present even with a therapeutic or subtherapeutic INR because the coagulopathy is not warfarin-driven alone
›Initial management
›Resuscitate with crystalloid and packed red blood cells as needed; avoid overcorrection that raises Doppler MAP above 90 mmHg
›Type and crossmatch early
›Endoscopic evaluation and hemostasis when the bleeding source is identified
›The anticoagulation dilemma
›Reversing or holding anticoagulation controls bleeding but raises pump thrombosis risk; continuing anticoagulation controls thrombosis risk but perpetuates bleeding
›Do not reverse anticoagulation reflexively; the decision requires the VAD team and, for major bleeding, hematology input balancing both risks
›For life-threatening hemorrhage, reversal takes priority
›Vitamin K 5-10 mg IV or PO
›4-factor prothrombin complex concentrate 25-50 units/kg IV for rapid INR correction
›Fresh frozen plasma 10-15 mL/kg IV if PCC unavailable
›Desmopressin (DDAVP) 0.3 mcg/kg IV once may improve platelet-mediated hemostasis in von Willebrand-related bleeding
›For minor or self-limited bleeding, anticoagulation is often continued or only briefly held, per VAD team guidance
›Aspirin management
›Aspirin 81 mg daily is the typical antiplatelet dose; hold only for major bleeding and per VAD team direction
›Immediate imaging determines pathway
›Non-contrast CT head first; do not attempt MRI
›CT angiography head and neck if ischemic stroke or large-vessel occlusion suspected
›Ischemic stroke
›Systemic thrombolysis is high-risk given baseline acquired coagulopathy and antithrombotic therapy; the decision requires neurology and the VAD team, not a routine stroke-pathway default
›If thrombolysis is being considered, alteplase dosing (when used) is 0.9 mg/kg IV, maximum 90 mg, 10% as bolus over 1 minute and the remainder over 60 minutes
›Mechanical thrombectomy for large-vessel occlusion within the eligible window is generally preferred over thrombolysis in this population when available
›Evaluate for pump thrombosis as the embolic source with LDH trend and controller parameters
›Hemorrhagic stroke
›Reverse anticoagulation urgently (see agents above) in coordination with neurosurgery and the VAD team
›Strict blood pressure control per standard intracerebral hemorrhage targets, using the Doppler MAP technique for monitoring
›Stroke, both ischemic and hemorrhagic combined, is the leading cause of death in continuous-flow LVAD patients
Right ventricular failure management
›Recognize the mechanism before treating
›LVAD support unloads the left ventricle and increases venous return to an already vulnerable right ventricle
›Excessive pump speed shifts the interventricular septum leftward, reducing right ventricular geometry and function; inadequate pump speed underdecompresses the left ventricle and worsens pulmonary congestion
›Speed adjustment is a VAD-team decision guided by echocardiography, not an independent ED intervention
›Fluids and pressors must be handled specifically
›Avoid volume loading in a congested right ventricle; this raises central venous pressure without improving forward flow and can worsen tricuspid regurgitation
›Avoid excessive vasoconstrictor dosing; pure alpha agents (phenylephrine 50-200 mcg IV bolus, or infusion 0.1-0.5 mcg/kg/min) raise pulmonary and systemic afterload and worsen right ventricular strain, and are generally avoided as first-line agents in this setting
›Norepinephrine 0.02-0.3 mcg/kg/min IV, titrated to Doppler MAP 70-90 mmHg, is preferred when vasopressor support is needed
›Inotropic and pulmonary vasodilator support
›Milrinone 0.125-0.5 mcg/kg/min IV infusion, no loading bolus in hypotension, reduce dose in renal impairment; reduces right ventricular afterload and augments contractility
›Dobutamine 2-20 mcg/kg/min IV infusion as an alternative inotrope; monitor for tachyarrhythmia
›Inhaled nitric oxide 20 ppm or inhaled epoprostenol as pulmonary vasodilators to selectively reduce right ventricular afterload without systemic hypotension
›Diuresis for volume-overloaded right ventricular failure
›Furosemide 40-80 mg IV bolus, titrate to urine output, monitor potassium and magnesium
›Refractory right ventricular failure
›Escalation to temporary right ventricular assist device or VA-ECMO is a VAD-team and cardiac surgery decision, not initiated independently in the ED
Suction events and aortic insufficiency management
›Suction event alarm signature
›Sudden low-flow alarm with abrupt drop in estimated flow and pulsatility index, often triggered by hypovolemia, tamponade, arrhythmia, or excessive pump speed relative to preload
›Suction event treatment is usually volume and reducing pump speed
›Small crystalloid bolus 250-500 mL, reassess flow after each bolus
›Contact the VAD team to reduce pump speed transiently; do not adjust speed independently outside of a life-threatening delay in reaching the team
›Troubleshooting node: if the suction event alarm does not resolve with volume
›Reassess for tamponade with point-of-care echocardiography
›Reassess for a new arrhythmia on continuous ECG
›Reassess for occult hemorrhage as the driver of hypovolemia
›Recurrent suction events despite these measures should prompt formal echocardiographic ramp study evaluation by the VAD team
›Aortic insufficiency mechanism
›Continuous unloading reduces aortic valve opening frequency over time, promoting valve degeneration and progressive regurgitation
›Regurgitant flow recirculates from the aorta back into the left ventricle and out through the pump, reducing the effective forward flow the pump delivers to the body despite normal-appearing pump parameters
›Aortic insufficiency diagnosis
›Echocardiography for regurgitant jet and valve opening frequency; formal ramp study if pump-flow contribution needs quantification
›Aortic insufficiency management
›Blood pressure control (Doppler MAP target 70-90 mmHg, avoiding higher values) reduces the regurgitant driving pressure
›Pump speed reduction to allow more native valve opening is a VAD-team decision guided by echocardiography
›Severe symptomatic aortic insufficiency may require surgical valve repair, percutaneous valve closure, or device exchange, decided with cardiac surgery and the VAD team
›Ventricular tachycardia may be surprisingly well tolerated
›Continued LVAD forward flow can maintain systemic perfusion during sustained VT because the pump output is largely independent of native left ventricular contraction
›Tolerance does not mean the arrhythmia can be ignored
›Sustained VT still stresses the right ventricle, which remains dependent on native contraction, and can precipitate right ventricular failure or a suction event
›Risk of degeneration to ventricular fibrillation remains
›Treatment
›Correct electrolytes: potassium target 4.0-5.0 mmol/l, magnesium target greater than 0.85 mmol/l, before or alongside antiarrhythmic therapy
›Amiodarone 150 mg IV over 10 minutes, may repeat once, then infusion 1 mg/min for 6 hours followed by 0.5 mg/min for 18 hours
›Synchronized cardioversion if hemodynamically unstable despite LVAD support (falling Doppler MAP, worsening mentation, low-flow alarm)
›ICD interrogation if a defibrillator is present; device shocks may occur and should prompt device and VAD-team review
›ECG monitoring
›Continuous ECG during antiarrhythmic loading and diuresis, given electrolyte shifts that prolong the QT interval and provoke recurrent ventricular arrhythmia
›Serial ECG for QT interval trend whenever potassium or magnesium is being actively repleted
›Atrial fibrillation or flutter
›Generally better tolerated hemodynamically than in a non-LVAD patient because the LVAD is preload- rather than rhythm-dependent, but rate control is still indicated to protect right ventricular function
›Metoprolol 2.5-5 mg IV every 5 minutes, maximum 15 mg, used cautiously and avoided if right ventricular failure or hypotension present
Iatrogenic harms in routine emergency department care
›Intubation and sedation
›RSI can precipitate profound hypotension or a suction event in this preload-dependent physiology; use ketamine or etomidate as above and have vasopressor support ready before induction
›Fluid loading
›Indicated for suspected hypovolemia or suction event, contraindicated in volume-overloaded right ventricular failure; distinguishing the two before giving fluid is essential
›Oxygen and pulse oximetry
›Not harmful, but do not trust pulse oximetry alone; confirm oxygenation with blood gas if the waveform is poor or absent
›Vasopressors
›Pure alpha agents and high-dose catecholamines raise afterload, reduce pump flow, and can precipitate or worsen right ventricular failure and aortic insufficiency; use the lowest effective dose and prefer norepinephrine over phenylephrine
›Mechanical circulatory support, including intra-aortic balloon pump
›Standard IABP placement is generally incompatible with or complicated by the existing outflow graft and valve anatomy; escalation to additional mechanical support (temporary RVAD, VA-ECMO) is a VAD-team and cardiac surgery decision, not an independent ED action
›Anticoagulation
›Do not reverse or hold empirically without weighing pump thrombosis risk; this is the central anticoagulation dilemma discussed under gastrointestinal bleeding
›Fibrinolysis
›High bleeding risk given baseline acquired von Willebrand syndrome and antithrombotic therapy; use only after specific discussion with neurology or cardiology and the VAD team, not as a default pathway step
›Analgesia
›Opioids can cause vasodilation and preload reduction; titrate cautiously
›NSAIDs (for example ibuprofen 400-600 mg PO every 6-8 hours, maximum 2400 mg per day) are generally avoided given bleeding risk from combined anticoagulation, antiplatelet therapy, and acquired coagulopathy
›Acetaminophen 650-1000 mg PO or IV every 6 hours, maximum 4 g per day (lower maximum in hepatic impairment), is the preferred first-line analgesic and antipyretic in this population